SynthesisDrugs2026

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials.

Wenmei Qiao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.